BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

729 related articles for article (PubMed ID: 16716153)

  • 1. Methotrexate and ciclosporin combination for the treatment of severe psoriasis.
    Aydin F; Canturk T; Senturk N; Turanli AY
    Clin Exp Dermatol; 2006 Jul; 31(4):520-4. PubMed ID: 16716153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial.
    Flytström I; Stenberg B; Svensson A; Bergbrant IM
    Br J Dermatol; 2008 Jan; 158(1):116-21. PubMed ID: 17986302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities.
    Balasubramaniam P; Stevenson O; Berth-Jones J
    Br J Dermatol; 2004 Apr; 150(4):741-6. PubMed ID: 15099371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial.
    Salim A; Tan E; Ilchyshyn A; Berth-Jones J
    Br J Dermatol; 2006 Jun; 154(6):1169-74. PubMed ID: 16704650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.
    Heydendael VM; Spuls PI; Opmeer BC; de Borgie CA; Reitsma JB; Goldschmidt WF; Bossuyt PM; Bos JD; de Rie MA
    N Engl J Med; 2003 Aug; 349(7):658-65. PubMed ID: 12917302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India.
    Kaur I; Dogra S; De D; Kanwar AJ
    Pediatr Dermatol; 2008; 25(2):184-8. PubMed ID: 18429775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort.
    Dalaker M; Bonesrønning JH
    J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):277-82. PubMed ID: 19207642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
    Puig L
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: a comparative study.
    Ranjan N; Sharma NL; Shanker V; Mahajan VK; Tegta GR
    J Dermatolog Treat; 2007; 18(5):295-300. PubMed ID: 17852635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
    Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.
    Kamili QU; Miner A; Hapa A; Menter A
    J Drugs Dermatol; 2011 May; 10(5):539-44. PubMed ID: 21533302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept combined with methotrexate for high-need psoriasis.
    Driessen RJ; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo.
    Kalb RE; Gurske J
    J Am Acad Dermatol; 2005 Oct; 53(4):616-22. PubMed ID: 16198781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
    Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacalcitol in the treatment of psoriasis vulgaris: the Spanish experience.
    Lecha M; Mirada A; López S; Artés M;
    J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):414-7. PubMed ID: 15987284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of ciclosporin in psoriasis.
    Berth-Jones J
    J Dermatolog Treat; 2005; 16(5-6):258-77. PubMed ID: 16428145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
    Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
    Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey.
    Nijsten T; Margolis DJ; Feldman SR; Rolstad T; Stern RS
    J Am Acad Dermatol; 2005 Mar; 52(3 Pt 1):434-44. PubMed ID: 15761421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The treatment of psoriasis vulgaris: 1% topical methotrexate gel.
    Eskicirak B; Zemheri E; Cerkezoglu A
    Int J Dermatol; 2006 Aug; 45(8):965-9. PubMed ID: 16911386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.